Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNK05047 in advanced solid tumors and DLBCL
NCT05487170Phase 2Recruiting
- Sponsor
- Ranok Therapeutics
- Start
- Jul 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of RNK05047 in solid tumor (advanced stage), diffuse large B-cell lymphoma (DLBCL), sponsored by Ranok Therapeutics. Started Jul 2022; status: recruiting.
02
Drugs
RNK05047
03
Conditions
solid tumor (advanced stage)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05487170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05487170.